Reserve concomitant prescribing of such prescription drugs in sufferers for whom other remedy selections are inadequate. Restrict dosages and durations to your minimal required. Monitor closely for signs of respiratory melancholy and sedation.
fentanyl intranasal and buprenorphine both of those boost sedation. Avoid or Use Alternate Drug. Limit use to patients for whom option treatment possibilities are insufficient
Drug is often abused in a method much like other opioids; contemplate this when prescribing or dispensing buprenorphine in predicaments when clinician is concerned about enhanced possibility of misuse, abuse, or diversion
hydroxyzine and buprenorphine both of those enhance QTc interval. Modify Therapy/Watch Intently. If coadministration necessary, take into account look at dose reduction of 1 or equally prescription drugs resulting from probable for additive pharmacological consequences
dabrafenib will lower the extent or impact of buprenorphine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
lonafarnib will boost the amount or effect of buprenorphine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
amobarbital will lower the extent or effect of buprenorphine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
buprenorphine decreases outcomes of fentanyl transdermal by pharmacodynamic antagonism. Steer clear of or Use Alternate Drug. Coadministration of combined agonist/antagonist and partial agonist opioid analgesics could cut down fentanyl's analgesic influence And maybe precipitate withdrawal indications.
Phone 911 or get crisis medical support immediately in all conditions of recognised or suspected opioid overdose, even when naloxone is administered.
primidone will minimize the level or result of buprenorphine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Stiripentol can be a CYP3A4 inhibitor and inducer. Keep track of CYP3A4 substrates coadministered with stiripentol for amplified or diminished results. CYP3A4 substrates could have to have dosage adjustment.
crofelemer will increase levels of buprenorphine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Crofelemer has the opportunity to inhibit CYP3A4 at concentrations envisioned during the intestine; not likely to inhibit systemically because minimally absorbed.
Reserve concomitant prescribing of these medicine in patients for whom other treatment choices are inadequate. Limit dosages and durations into the minimal click here needed. Keep an eye on intently for signs of respiratory despair and sedation.
Speak to your health care provider without delay For those who have any adjustments for your coronary heart rhythm. You may feel dizzy or faint, or You may have a quick, pounding, or uneven heartbeat. Ensure that your health care provider is aware of should you or any one in your family has ever had a coronary heart rhythm problem including QT prolongation.